Newer antibiotics for musculoskeletal infections

Indian Journal of Rheumatology

Volumn 6, Issue 1 SUPPL., 2011, Pages 80-86

  Pawar, Dilip ^a   Bhandari, Prasan ^b  

^a Dr Reddys Research Laboratories   (India)

^b SDM COLLEGE OF MEDICAL SCIENCES AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERICIDE; BETA LACTAM ANTIBIOTIC; CEFRADINE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; PSEUDOMONIC ACID; QUINOLONE; RIFAMPICIN; STREPTOGRAMIN; TEICOPLANIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ALPHA HEMOLYTIC STREPTOCOCCUS; ANEMIA; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIAL ARTHRITIS; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD LEVEL; BONE INFECTION; BONE MARROW SUPPRESSION; CLOSTRIDIUM DIFFICILE INFECTION; DEVICE REMOVAL; DIABETIC FOOT; DIARRHEA; DRUG BIOAVAILABILITY; ENTEROCOCCACEAE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEALING; HIP ARTHROPLASTY; HUMAN; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; KNEE ARTHROPLASTY; LISTERIA MONOCYTOGENES; LIVER FAILURE; MACROPHAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROSTHETIC JOINT INFECTION; PSEUDOMEMBRANOUS COLITIS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; SURGICAL DRAINAGE; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS; VASCULAR DISEASE; VOMITING;

EID: 84992231728     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(11)60037-X     Document Type: Review

References (87)

1. Darley ESR, Alasdair P. MacGowan. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53: 928-35. (Pubitemid 38811422)
2. Sax H, Lew D. Osteomyelitis. Curr Infect Dis Rep 1099; 1: 261c6.
3. Waldvogel FA, Vasey H. Osteomyelitis: the past decade. New Eng J Med 1980; 303: 360-70. (Pubitemid 10035062)
4. Goldenberg DL. Septic arthritis. Lancet 1998; 351: 197-202. (Pubitemid 28037017)
5. th edition. Philadelphia, PA, USA: Churchill Livingstone, 2000: 1196-200.
6. Oliker R, Cunha BA. Streptococcus pneumoniae septic arthritis and osteomyelitis in an HIV-seropositive patient. Heart Lung 1999; 28: 74-6. (Pubitemid 29055086)
7. Allberger F, Kasten MJ, Cockerill FR, et al. Listeria monocytogenes infection in prosthetic joints. Int Ortho 1992; 16: 237-9.
8. Massarotti EM, Dinerman H. Septic arthritis due to Listeria monocytogenes: report and review of the literature. J Rheumatol 1990; 17: 111-3. (Pubitemid 20070581)
9. Goldstein EJC. Bite wounds and infection. Clin Inf Dis 1991; 14: 633-40.
10. Bell SM. Further observations on the value of oral penicillins in chronic staphylococcal osteomyelitis. Med J Aust 1976; 2: 591-3.
11. Hodgin UG. Antibiotics in the treatment of chronic staphylococcal osteomyelitis. South Med J 1975; 68: 817-23.
12. Cole WG, Dalziel RE, Leitl S. Treatment of acute osteo myelitis in childhood. J Bone Joint Surg 1982; 64B: 218-23. (Pubitemid 12003193)
13. Kaplan SL, Mason EO, Feign RD. Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children. South Med J 1982; 75: 138-42. (Pubitemid 12128106)
14. Kolyvas E, Aronheim G, Marks MI, et al. Oral antibiotic therapy of skeletal infections in children. Pediatrics 1980; 65: 8667-71.
15. Rodriguez W, Ross S, Khan W, et al. Clindamycin in the treatment of osteomyelitis in children. Am J Dis Child 1977; 131: 1088-93.
16. Tetzlaff TR, McCracken GH, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteo myelitis and suppurative arthritis. J Pediatr 1978; 92: 485-90. (Pubitemid 8296517)
17. Cunha B. Antibiotics in orthopaedic infections. In Orthopaedic Infection. Schlossberg D (Ed.), New York, USA: Springer-Verlag, 1988: 156-74.
18. Fitzgerald RH, Kelly PJ, Snyder RJ, et al. Penetration of methicillin, oxacillin and cephalothin into bone and synovial tissues. Antimicrob Agents Chemother 1978; 14: 723-6. (Pubitemid 9045860)
19. Sattar MA, Barrett SP, Cawley MID. Concentrations of some antibiotics in synovial fluid after oral administration, with some special reference to antistaphylococcal activity. Ann Rheum Dis 1983; 46: 67-74. (Pubitemid 13148343)
20. Mader JT, Mohan D, Calhoun J. A practical guide to the diagnosis and management of bone and joint infections. Drugs 1997; 54: 235-64.
21. Cunha BA. The use of penicillins in orthopaedic surgery. Clin Orthop 1984; 190: 36-49. (Pubitemid 15223463)
22. Collins D, McKenzie JM. Infections at the site of a hip implant. Clin Orthop 1991; 269: 9-15.
23. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopaedic prostheses. Clin Infect Dis 1998; 27: 711-3. (Pubitemid 29244322)
24. Tattevin P, Crémieux AC, Pottier P, et al. Prosthetic joint infection: when can prosthesis salvage be considered? Clin Infect Dis 1999; 2: 292-5.
25. Atkins BL, Bowler ICJW. The diagnosis of large joint sepsis. J Hosp Infect 1998; 40: 263-74. (Pubitemid 28552393)
26. Gristina AG, Costerton JW. Bacterial adherence to biomaterials and tissue. J Bone Joint Surg 1985; 67A: 264-73.
27. Lieberman JR, Callaway GH, Salvati EA, et al. Treatment of the infected hip arthroplasty with a two-stage reimplantation protocol. Clin Orthop 1994; 301: 205-12. (Pubitemid 24119275)
28. Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint arthroplasty. Clin Orthop Relat Res 2003; 414: 55-60. (Pubitemid 37102135)
29. Brandt CM, Sisitrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24: 914-9. (Pubitemid 27193877)
30. Mader JT, Calhoun J. Osteomyelitis. In Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th edn, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia, PA, USA, 2000: 1182-96.
31. Black J, Hunt TL, Godley PJ, et al. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. J Infect Dis 1987; 155: 968-72. (Pubitemid 17062834)
32. Norden C, Shaffer M. Treatment of experimental chronic osteomyelitis due to Staphylococcus aureus with vancomycin and rifampicin. J Infect Dis 1983; 147: 352-7. (Pubitemid 13195121)
33. Verklin RM, Mandell GL. Alteration of effectiveness of antibiotics by anaerobiosis. J Lab Clin Med 1976; 89: 65-71. (Pubitemid 8025457)
34. Lovering AM, Perez AM, Bowker KE, et al. A comparison of the penetration of cefuroxime and cephamandole into bone, fat and haematoma fluid in patients undergoing total hip replacement. J Antimicrob Chemother 1997; 40: 99-104. (Pubitemid 27341639)
35. Gisby J, Beale AS, Bryant JE, et al. Staphylococcal osteomyelitis - a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J Antimicrob Chemother 1994; 34: 755-64.
36. Schurman DJ, Johnson L, Finerman G, et al. Antibiotic bone penetration. Clin Orthop 1975; 111: 142-6.
37. Unsworth PF, Heatley FW, Philips I. Flucloxacillin in bone. J Clin Pathol 1978; 31: 705-11. (Pubitemid 9010936)
38. Hooper JA, Wood AJJ. Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384-94.
39. Desplaces N, Acar JF. New quinolones in the treatment of joint and bone infections. Rev Infect Dis 1988; 10(Suppl 1): S179-83.
40. Dellamonica, P, Bernard, E, Etesse, H. et al. The diffusion of pefloxacin into bone and the treatment of osteomyelitis. J Antimicrob Chemother 1986; 17(Suppl B): 93-102.
41. Giammarellou, H. Activity of quinolones against Gram-positive cocci: clinical features. Drugs 1995; 49(Suppl 2): 58-66.
42. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999-1007.
43. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25: 1327-33. (Pubitemid 28022665)
44. Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991; 16: 1279-85.
45. Drancourt M, Stein A, Argenson JN, et al. Oral rifampicin plus ofloxacin for treatment of Staphylococcus-infected ortho paedic implants. Antimicrob Agents Chemother 1993; 37: 1214-8. (Pubitemid 23166716)
46. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones'. J Antimicrob Chemother 1999; 43(Suppl B): 1-11.
47. Norden CW. Experimental osteomyelitis. IV. Therapeutic trials with rifampicin alone and in combination with gentamicin, sisomycin and cephalothin. J Infect Dis 1975; 132: 493-9.
48. Yourassowksy E, Van der Linden MP, Lismont MJ, et al. Combination of minocycline and rifampicin against methicillinand gentamicin-resistant Staphylococcus aureus. J Clin Pathol 1981; 34: 559-63. (Pubitemid 11063967)
49. Zinner SH, Lagast H, Klastersky J. Antistaphylococcal activity of rifampicin with other antibiotics. J Infect Dis 1981; 144: 365-71. (Pubitemid 11017969)
50. Zimmerli W, Widmer A, Blatter M, et al. Role of rifampicin for treatment of orthopaedic implant-related staphylococcal infections. JAMA 1998; 279: 1537-41. (Pubitemid 28233008)
51. Widmer AF, Gaechter A, Ochsner PE. Antimicrobial treatment of orthopaedic implant-related infections with rifampicin combinations. Clin Infect Dis 1992; 14: 1251-3.
52. Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40. (Pubitemid 27116419)
53. Clumeck N, Marcelis L, Amiri-Lamraski MH, et al. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984; 13(Suppl C): 17-22. (Pubitemid 15122808)
54. Yzerman EPF, Boelens HAM, Vogl M, et al. Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. J Antimicrob Chemother 1998; 42: 233-9. (Pubitemid 28393593)
55. Chater EH, Flynn J. Fucidin levels in osteomyelitis. Ir Med J 1972; 65: 506-8.
56. Lautenbach EEG, Robinson RG, Koornhof HJ. Serum and tissue concentrations of sodium fusidate in patients with chronic osteomyelitis and in normal volunteers. S Afr J Surg 1975; 13: 21-32.
57. Bailey EM, Ryback MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991; 35: 1089-92.
58. Wood M. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22. (Pubitemid 26123160)
59. Wilson APR, GrFCneberg RN. Safety. In Teicoplanin: The First Decade. The Medicine Group (Education) Ltd, Abingdon, Oxfordshire, UK, 1997: 143.
60. Darley E, MacGowan A. Antibiotic treatment of Gram-positive bone and joint infection. J Antimicrob Chemother 2004; 53: 928-35. DOI: 10.1093/jac/dkh191. (Pubitemid 38811422)
61. Henry N, Roues M, Whitesell A. Treatment of methicillin resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampicin. Am J Med 1987; 82(Suppl 4A): 73-5.
62. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55. DOI: 10.1016/S1473-3099(01)00091-3. (Pubitemid 33586048)
63. Ward PB, Johnson PD, Grabsch EA, Mayall BC, Grayson ML. Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust 2001; 175: 480-3. (Pubitemid 33039860)
64. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 2005; 11(Suppl 4): 33-42. DOI: 10.1111/j.1469-0691. 2005.01162.x. (Pubitemid 40946170)
65. Graber CJ, Wong MK, Carleton HA, Perdreau-Remington F, Haller BL, Chambers HF. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 2007; 13: 491-3. (Pubitemid 46348141)
66. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005; 21: 1923-6. DOI: 10.1185/030079905X74961. (Pubitemid 41803101)
67. Saleh-Mghir A, Ameur N, Muller-Serieys C, et al. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob Agents Chemother 2002; 46: 1122-4. DOI: 10.1128/AAC.46.4.1122-1124.2002. (Pubitemid 34260365)
68. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46: 775-84. DOI: 10.1093/jac/46.5.775.
69. Package insert. Synercid (quinupristin/dalfopristin) Monarch Pharmaceuticals, Bristol, 2003.
70. Bassetti M, Righi E, DiBiagio A, Rosso R, Beltrame A, Bassetti D. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect Ther 2005; 3: 343-52. DOI: 10.1586/14787210.3.3.343. (Pubitemid 40872529)
71. Package insert. Zyvox (linezolid). Pharmacia & Upjohn Co Div of Pfizer Inc., New York, 2007.
72. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-63. DOI: 10.1016/j.clinthera.2006.08.001. (Pubitemid 44374746)
73. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-9. DOI: 10.1016/j.ijantimicag.2006.08.030. (Pubitemid 46240739)
74. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45: 2154-6. DOI: 10.1128/AAC.45.7.2154-2156.2001. (Pubitemid 32591718)
75. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8. DOI: 10.1016/S0140-6736(01)05410-1. (Pubitemid 32718546)
76. Package insert. Tygacil (tigecycline). Wyeth Pharmaceuticals, Philadelphia, 2007.
77. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 28: 1079-106. DOI: 10.1016/j.clinthera. 2006.08.011. (Pubitemid 44376809)
78. Qadri SMH, Halim M, Ueno Y, et al. Susceptibility of methicillin- resistant Staphylococcus aureus to minocycline and other antimicrobials. Chemotherapy 1994; 40: 26-9. (Pubitemid 23360159)
79. Yuk JH, Dignani MC, Harris RL, et al. Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 1991; 13: 1023-4.
80. Stein A, Bataille JF. Drancourt M, et al. Ambulatory treatment of multidrug-resistant Staphylococcus aureus-infected orthopaedic implants with high dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agent Chemother 1998; 42: 3086-91. (Pubitemid 28553722)
81. Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-25.
82. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24: 41-57. DOI: 10.1592/phco.24.1.41.34802.
83. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45: 1799-802. DOI: 10.1128/AAC.45.6.1799-1802.2001. (Pubitemid 32466351)
84. Ammerlaan HS, Bonten MJ. Daptomycin: graduation day. Clin Microbiol Infect 2006; 12(Suppl 8): 22-8. DOI: 10.1111/j.1469-0691.2006.01627.x. (Pubitemid 44697893)
85. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82. DOI: 10.1128/AAC.50.3.1079-1082.2006. (Pubitemid 43327815)
86. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers. Diag Microbiol Infect Dis 2005; 53: 329-32. DOI: 10.1016/j.diagmicrobio.2005.07.001. (Pubitemid 41796907)
87. th interscience conference on antimicrobial agents and chemotherapy, San Francisco, 2006: 27-30. Abstract 1536.